Acquisition strengthens growing network’s resources to service pharmaceutical and research partners globally
LMC Manna Research – the largest network of fully-owned and integrated clinical research sites in Canada providing Phase I-IV clinical trial services – recently announced the acquisition of leading Montreal-based research centre Omnispec Clinical Research. Having contributed to the development of more than 60 drugs, Omnispec adds greater capacity, data and talent to the LMC Manna Research network, creating additional research opportunities with its pharmaceutical and research partners globally.
“We are excited to join forces with such a highly-qualified and reputable research site that has a long and successful track record in clinical trial delivery,” said Karri Venn, President of Research of LMC Manna Research. Omnispec increases the LMC Manna Research total network to 19 sites across the country.
“Omnispec is an excellent fit with our continued objective to leverage a centralized network as a means to streamline study start-up and patient enrollment, and deliver high-quality clinical research with unparalleled efficiency,” she said.
Founded in 2005 by general practitioner Dr. Guy Tellier, Omnispec has extensive experience conducting Phase II, III and IV clinical trials on behalf of the pharmaceutical industry, including studies in the areas of diabetes, obesity, chronic obstructive pulmonary disease (COPD), lipids and vaccine development. Its expert staff operates out of a large facility that includes a state-of-the-art lab, and is associated with a large medical clinic that supports recruitment.
Under terms of the agreement, Omnispec will operate as an integrated LMC Manna Research site, with Dr. Tellier assuming the role of Medical Director for the Montreal site, located in the suburb of Mirabel. “For the most part, our business will run exactly the same, but now we have excellent new technologies and a sophisticated infrastructure at our disposal to leverage and enhance our enrollment capabilities, allowing us to participate in even more high-quality studies,” said Dr. Tellier, who anticipates activity at the Montreal site to grow by 50 percent or more following the acquisition.
“We’re very proud of our history working according to stringent Health Canada and FDA regulations, and we look forward to sharing our expertise with the entire LMC Manna Research network,” he added.
Canada’s most extensive clinical research network, LMC Manna Research provides pharmaceutical sponsors and contract research organizations with a single source approach to performing clinical trials across a full gamut of treatment areas. Its proven track record of fast start-up, high recruitment and quality regulatory compliance is supported by its ability to provide single-source contracting, integrated standard operating procedures, strong quality assurance and quality control mechanisms and new technology across its entire network.
About LMC Manna Research
LMC Manna Research is an industry leader, providing Phase I-IV clinical trial services across Canada at 19 active research sites across Canada. It is the largest clinical research site group in the country and one of the largest research site networks in the world. The company is also the world’s largest group specialized in diabetes, lipid, metabolic and endocrinology research. Over the past 20 years, the company has completed more than 1,600 studies to help evaluate hundreds of new drugs and treatments in more than 18,000 patients and has won numerous awards for performance, quality, and innovation. For more information, visit http://lmcmannaresearch.com.